Arthur F. Golden - 21 Nov 2025 Form 4 Insider Report for Turn Therapeutics Inc. (TTRX)

Role: Director
Signature: /s/ Zuraiz Chaudhary, attorney-in-fact for Arthur Golden
Issuer symbol: TTRX
Transactions as of: 21 Nov 2025
Net transactions value: +$58,927
Form type: 4
Filing time: 24 Nov 2025, 07:13:06 UTC
Previous filing: 23 Oct 2025
Next filing: 25 Nov 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
GOLDEN ARTHUR F	Director	C/O TURN THERAPEUTICS INC., 250 N. WESTLAKE BLVD., WESTLAKE VILLAGE	/s/ Zuraiz Chaudhary, attorney-in-fact for Arthur Golden	24 Nov 2025	0001023260

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TTRX	Common Stock	Purchase	$58,927	+20,532	+68%	$2.87	50,734	21 Nov 2025	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Certain of the securities reported in Column 5 of Table I are restricted stock units ("RSUs") granted under the Issuer's 2025 Omnibus Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock, subject to the applicable vesting schedule and the reporting person's continuous service through the vesting date.
F2	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.66 to $3.25, inclusive. The Reporting Person undertakes to provide to Turn Therapeutics Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Content

Certain of the securities reported in Column 5 of Table I are restricted stock units ("RSUs") granted under the Issuer's 2025 Omnibus Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock, subject to the applicable vesting schedule and the reporting person's continuous service through the vesting date.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.66 to $3.25, inclusive. The Reporting Person undertakes to provide to Turn Therapeutics Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.